Abstract:// Chang Liu 1, * , Guo-Jun Zeng 2, * , Bang-Sheng Jia 3 , Jia-Yin Yang 1 , Li Jiang 1 , Hua Du 1 , Wu-Ran Wei 4 , Bing-Wen Zou 5 and Wu-Sheng Lu 1 1 Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, 610041, China 2 Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China 3 Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610041, China 4 Department of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China 5 Division of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China * These authors contributed equally to this work Correspondence to: Wu-Sheng Lu, email: luwu8@126.com Keywords: neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; hepatocellular carcinoma (HCC); transarterial chemoembolization (TACE); 131 I-labeled-metuxima (Licartin) Received: May 27, 2017 Accepted: November 08, 2017 Published: January 02, 2018 ABSTRACT Background: The prognostic value of NLR and PLR in unresectable HCC patients undergoing 131 I-labeled-metuximab plus transarterial chemoembolization has not been studied. Materials and Methods: 184 patients with unresectable HCC were enrolled from 2009 to 2011. Data were acquired through patients' medical records and follow-up. Receiver operating curves (ROC) were used to determine the optimal cut-off levels of NLR and PLR. Kaplan-Meier univariate analysis and multivariate Cox regression analysis were used to evaluate the correlation of the NLR, PLR, and other potential prognostic factors with overall survival. Results: The optimal cutoff levels were 2.5 for NLR and 105 for PLR by ROC curve analysis. Patients with NLR ≥ 2.5 and PLR ≥ 105 groups had significantly worse OS. The median survival time for patients with low NLR and high NLR were 19 months (2–35 months) and 10 months (2–34 months) respectively. And median survival time were 13 months (2–35 months) and 21 months (2–35 months) in the high and low PLR group respectively. Multivariate analysis showed that NLR ≥ 2.5 (HR, 2.41; 95% CI, 1.26–4.13; P = 0.034, PLR ≥ 105 (HR, 1.79; 95% CI, 1.17–3.41; P = 0.028), tumor ≥ 10 cm (HR, 1.81; 95% CI, 1.04–2.62; P = 0.016), BCLC C stage (HR,3.12; 95% CI, 1.72–4.98; P = 0.021) and albumin 35 < g/L (HR, 0.56; 95% CI, 0.34–0.95; P = 0.03) were independent risk factors for OS. Conclusions: Elevated NLR and PLR were independent factors of a poor prognosis in unresectable patients undergoing 131 I-labeled-metuximab plus TACE.

A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma

Preoperative Neutrophil-to-lymphocyte Ratio is an Independent Prognostic Predictor for AFP Negative Hepatocellular Carcinoma after Hepatectomy

The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation

Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.

Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma

Combination of Preoperative Circulating Tumor Cell Count and Neutrophil-Lymphocyte Ratio for Prognostic Prediction in Hepatocellular Carcinoma Patients after Curative Hepatectomy

Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

The lymphocyte-to-monocyte ratio is a superior predictor of overall survival compared to established biomarkers in HCC patients undergoing liver resection

Preoperative Plus Postoperative Neutrophil-Lymphocyte Ratio for Predicting Overall Survival Following Partial Hepatectomy for Hepatocellular Carcinoma

Neutrophil and Platelet-to-lymphocyte Ratio Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Undergoing 131I-Labeled-metuximab Plus Transarterial Chemoembolization

Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma

Prognostic Significance of Lymphocyte-to-monocyte Ratio and Platelet-to-lymphocyte Ratio in Patients with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization and Radiofrequency Ablation

Elevated Preoperative Neutrophil-Lymphocyte Ratio Is Associated with Poor Prognosis in Hepatocellular Carcinoma Patients Treated with Liver Transplantation: A Meta-Analysis

An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments

Therapeutic effect of postoperative adjuvant transcatheter arterial chemoembolization based on the neutrophil-to-lymphocyte ratio

A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

Neutrophil-lymphocyte Ratio Predicts the Prognosis of Patients with Hepatocellular Carcinoma after Liver Transplantation.

Neutrophil-to-lymphocyte ratio as an index of treatment response to trans-arterial chemoembolization in hepatocellular carcinoma

Neutrophil-to-lymphocyte and Aspartate-to-alanine Aminotransferase Ratios Predict Hepatocellular Carcinoma Prognosis after Transarterial Embolization

Using Pre-Treatment Neutrophil-to-Lymphocyte Ratio to Predict the Prognosis of Young Patients with Hepatocellular Carcinoma Implemented Minimally Invasive Treatment.